Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
08 août 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Positive INTERCEPT-AD Phase 1 trial results announced in July 2023 demonstrate ACU193’s potential as a differentiated antibody for the treatment of early Alzheimer’s diseaseCash, cash equivalents and...
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
01 août 2023 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...
Acumen Announces Pricing of Upsized $130 Million Public Offering
18 juil. 2023 22h31 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 18, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen”) (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel...
Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
17 juil. 2023 16h53 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
17 juil. 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023
16 juil. 2023 03h00 HE
|
Acumen Pharmaceuticals, Inc.
Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody ...
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease During Featured Research Session at the Alzheimer’s Association International Conference (AAIC®) 2023
13 juin 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Topline results for ACU193, the first clinical stage amyloid beta oligomer (AβO)-directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early...
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
09 mai 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable...
Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference
04 mai 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
02 mai 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing...